Skip to content

Financial Information

This section of the Karyopharm Therapeutics InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing. 

Please note:  All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes.  Karyopharm Therapeutics assumes no responsibility for the accuracy of this data and provides it for informational purposes only.

NASDAQKPTI
Beta0.97
Shares Outstanding73.6M
Average Volume (10 days)1.1M
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)($2.90)
Sales (TTM)$1.24
Book Value (MRQ)$1.14
Cash Flow (TTM)($2.43)
Cash (MRQ)$3.58

Analyst Views

Current Mean RecommendationStrong Buy
Strong Buy6
 
Buy1
 
Hold1
 
Underperform0
 
Sell0
 

Recent Insider Transactions

Christopher Brett Primiano
EVP, CBO, GC & Secretary
(38,550)
Sell
Oct 13, 2020
Christopher Brett Primiano
EVP, CBO, GC & Secretary
(721)
Sell
Oct 13, 2020
Michael G. Kauffman
Director, Chief Executive Officer
(7,500)
Sell
Oct 12, 2020
Sharon Shacham
President & CSO
(7,500)
Sell
Oct 12, 2020
Christopher Brett Primiano
EVP, CBO, GC & Secretary
(10,054)
Sell
Sep 8, 2020

Recent SEC Filings

Insider Buy/Sell
Nov 4, 2020
Insider Buy/Sell
Nov 4, 2020
Insider Buy/Sell
Nov 4, 2020
Quarterly Financials
Nov 2, 2020
Company Events
Nov 2, 2020
I agree to the storing and processing of my personal data by Karyopharm as described in the Privacy Policy and to the Terms of Use . I agree to receive communications from Karyopharm and understand that I can unsubscribe at any time.